Clinical trial
Study Evaluating Tigecycline in Selected Serious Infections Due to Resistant…
NCT00079989 · Wyeth is now a wholly owned subsidiary of Pfizer, Industry · Completed
Key facts
| NCT number | NCT00079989 |
|---|---|
| Title | Study Evaluating Tigecycline in Selected Serious Infections Due to Resistant Gram-Negative Organisms |
| Official title | A Phase 3, Open-label, Noncomparative Study of Tigecycline for the Treatment of Subjects With Selected Serious Infections Due to Resistant Gram-negative Organisms Such as Enterobacter Species, Acinetobacter Baumannii, and Klebsiella Pneumoniae |
| Lead sponsor | Wyeth is now a wholly owned subsidiary of Pfizer, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Gram-Negative Bacterial Infections |
| Intervention type | Drug |
| Interventions | tigecycline |
| Enrollment | 115 |
| Start date | Dec 1, 2003 |
| Primary completion | Nov 1, 2005 |
| Completion | Nov 1, 2005 |
| First posted | Mar 23, 2004 |
| Last update posted | Feb 8, 2013 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: